Finanzen von Sana Biotechnology Inc (SANA)SANASana Biotechnology Inc

Evaluating the bottom line, Sana Biotechnology, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -152.87%, provide a clear picture of how effectively SANA converts its operational activities into shareholder value.

In the context of the broader market, SANA competes directly with industry leaders such as ODTX and GLUE. With a market capitalization of $1.06B, it holds a significant position in the sector. When comparing efficiency, SANA's gross margin of N/A stands against ODTX's N/A and GLUE's 100.00%. Such benchmarking helps identify whether Sana Biotechnology, Inc. is trading at a premium or discount relative to its financial performance.

Sana Biotechnology has a current ratio of 1.38, indicating it has enough current assets to cover its liabilities, which is a positive sign for liquidity. However, the company has been consistently reporting negative net income, with losses reaching $63.6 million in Q2 2026.